[Hypogonadism and chronic obstructive pulmonary disease].
Chronic obstructive pulmonary disease (COPD) is a systemic disease that affects not only the respiratory system. Sex hormones deficiency in men can be correlated with the COPD stages and make a negative contribution during its progression. Up to date, there are no long-term trials evaluating the effects of androgens on the parameters of respiratory function in patients with COPD. Changes of testosterone levels in patients with COPD correlate with forced expiratory volume, and hypoxemia and hypercapnia levels. Glucocorticosteroids exacerbate androgen deficiency in patients with COPD, and the use of hormone replacement therapy with testosterone in these patients is justified. Androgens, in particular drug nebido, testosterone depot, can be effectively used in treatment and rehabilitation of patients with COPD.
A L
AL
Vertkin
L Iu
LIu
Morgunov
Kh A
KhA
Shakhmanaev
D000728:Androgens / Q000627:therapeutic use*; D006801:Humans; D006935:Hypercapnia / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D007006:Hypogonadism / Q000097:blood / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D000860:Hypoxia / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D013739:Testosterone / Q000031:analogs & derivatives* / Q000097:blood* / Q000627:therapeutic use
D000728:Androgens; D013739:Testosterone; C010792:testosterone undecanoate